The paper demonstrates the progress made in biomedical photonics engineering at Loughborough University since 1998. Research, development of concepts and innovation of products for principal use in healthcare can be traced back to the initial clinical request for a device to measure oxygen saturation in the peripheral tissues. Since then a directed path of progress, which has involved a systematic investigation of component technologies, has been followed. Latterly, the research has been directed at placing the devices developed at the point of care, which is often in the home setting rather than in a controlled clinical environment. Knowledge transfer of ideas and concepts through to translational research that utilises results can also be represented via the developed innovation platform.
Introduction
The innovations in the personalisation of healthcare devices described in this paper traces the development of ideas and concepts in physiological measurement that uses photoplethysmography (PPG) as its main component. In traditional clinical studies PPG provides information about oxygen saturation of arterial blood. This representation is extended to obtain a measurement of blood perfusion in a localised tissue area in the first instance, termed a sustained change. A more disruptive change can be seen when these advances in research and development lead to the biophotonic imaging of peripheral tissue, with pointers towards the achievement of high resolution 3-D images. As will be demonstrated, the innovations have two dimensions: the first is the transformation of 'blue sky' ideas to a product; the second is the technological change from a hospitalbased clinical measurement system to a physiological monitoring system useful for applications in home care. Throughout both dimensions of the study the research has been clinically driven and there are a number of clinical applications -so called use cases -that can be highlighted.
A general model of the research and innovation pipeline adopted within UK universities can be described as a voyage from the 'blue sky' ideas, through development of that idea into a research prototype. Typically, this first component of the model is funded through research grant awards from what can be diverse funding sources -UK Research Councils (for biomedical applications notably the Engineering and Physical Sciences Research Council, the Medical Research Council and the Biotechnology and Biological Sciences Research Council), direct from UK Government Departments (e.g. the Department of Health); a number of Trusts may have designated calls for proposals (e.g. The Wellcome Trust) and the many medical or health-related charities. From an international perspective the EU Framework Programme is an attractive option and there are often joint calls for proposals between the UK/EU and other countries. A recent challenge to research proposers is the change in funding model adopted by the UK Government and its Research Councils to one that is termed full economic costs. An unintended consequence of this change is that as charities and some Trusts have not adopted this model, a two tier funding system is in operation. 'High quality' research has become a misnomer that represents the origin of the funding rather than an indicator of what has been achieved.
At the same time as these changes in methods of funding, there has also been a perceptible shift in universities in the UK to market not only the expertise of their academic staff, but also the findings of research. So, the second component of the pipeline model is the development of the research prototype which requires the management of innovation and entrepreneurship. In common with other UK universities, Loughborough University has seen an increase in the staff and activity of the Intellectual Property Office. Funding for this component can be more difficult as the number of available sources is very much less than the research component and what is available is usually obtained via third party involvement that dilutes the scientific offering. Although in general terms the staff of the Intellectual Property Office in universities undoubtedly provide value, they may not have the same cultural involvement with the research to be marketed as those more directly involved. A further way in which to engage with the Intellectual Property Office of a UK university is to form a spin-out company where the researchers and the university (through a chosen representative) begin a co-operative partnership. This route is good for first-time entrepreneurs to obtain funding to further develop an idea or prototype. The work described has seen the development of ideas spun off via two such companies that are both still prospering from third party support.
outline of Principles of Measurement
PPG is a physiological measurement technique that measures arterial pulsations in vivo, based on optical properties of the interaction of light intensity variation with biological tissue. An attractive feature of the technique is that it provides real-time signals that are non-invasive, safe and painless. The underpinning measurement technology is centred on the assumption that changes in reflected (or transmitted) light intensity occur as a consequence of changes in blood volume. In fact the changes in blood volume provide the dynamic www.instmc.org.uk Measurement + Control Vol 44/6 July 2011 • 187 Themed Paper: Innovations Towards Personalised Biomedical Photonic Devices pulse form that is reproducible with respect to time and give a characteristic waveform. Differences in the waveform provide clinicians with diagnostic information, although it must be remembered that the waveform changes its shape and amplitude as the arterial pulse travels further from the heart.
The light-tissue interaction is dependent on the wavelength of the light source, with longer wavelengths being able to penetrate deeper into the tissue. Although the PPG signal can be generated in one of two modes -transmission (where light source and photodetector are placed on opposite sides of the vascular bed and operate via light that is transmitted through the tissue) and reflection (where the light source and photodetector are adjacent to one another and operate via light that is back-scattered through the tissue), only the latter is considered as a means for further development.
The PPG signal can be decomposed into two major components: the rapidly alternating yet small signal caused by arterial pulsations (giving rise to the AC signal component) and the relatively stable signal that emanates from bone and other tissue (giving rise to the DC component). The Beer-Lambert law is used to provide the theoretical underpinning of models that relate to the interactions of light with matter and is therefore utilised in models of the PPG signal. It states that the intensity of light (I) is a function of path length through which the light travels (r) and the absorbance constant (µ) for a given tissue at a given wavelength (λ) as follows:
Here r is measured in cm; µ(λ) in cm -1
; I 0 the light source intensity and I the light received at the photodetector is measured in Wsr -1 . In reality the absorbance coefficient is split into component parts depending on the type of tissue met. A current question that concerns the research group at Loughborough University is the continued applicability of the Beer-Lambert law in its current form for advanced PPG applications that involve 2-D and 3-D imaging.
Research and Innovation Pipeline
A time-line of research landmarks is shown in Table 1 below and provides relevant doctoral level research work that has contributed to the development of the PPG technologies, alongside the innovation steps that have contributed to the research and innovation platform.
Matthew Hayes work on artifact reduction in the PPG signal, completed in 1998, acted as the precursor to future effort in biophotonics measurement technology. Two threads become identifiable: how to reduce movement artifact by investigating a non-invasive method for data collection; and looking at oxygen saturation in the peripheral tissues. A couple of years later Vincent Crabtree provided a viable and repeatable technique for assessing peripheral vascular disease in lower limbs. Two PhDs were awarded in 2009 to members of the team: evaluation of venous oximetry was the subject of Angelos Echiadis' thesis, while Sharon Cheang's study investigated non-contact transmission PPG.
For non-contact oxygen saturation monitoring from a designated tissue, information from the venous side as well as the arterial side is required. It can be taken as given that conventional PPG is appropriate for the measurement of arterial oxygen saturation.
The following two methods will be used as exemplars to the innovations uncovered: venous oximetry and PPG imaging (IPPG). The research components that covered venous oximetry resulted in a product called 'Venox'. The Venox technologies constitute a novel and unique method for the non-invasive measurement of venous oxygen saturation (SvO 2 ). The Venox system can provide enhanced monitoring of cardiovascular function and as such has wide implications for clinical practice, health promotion and human performance assessment. No similar technology exists for monitoring the oxygen levels in the venous system and hence the consumption and/or demand for oxygen by the tissues. Existing pulse oximeters can only measure arterial oxygen saturation due to the fact that their principle of operation relies on the presence of arterial pulsations. Venous blood flow does not present any pulsations and as a consequence conventional pulse oximetry cannot detect venous oxygen saturation. By introducing a series of pulsations of known low frequency via a finger sphygmomanometer, a pulsatile venous flow can be induced. By applying similar techniques to conventional pulse oximetry the Venox system can distinguish between arterial and venous components of the pulsatile blood flow, and therefore it is possible to measure venous oxygen saturation. As both arterial oxygen saturation (input to tissues) and venous oxygen saturation (output from tissues) are now known, the tissue oxygen consumption can be derived. A patent for the Venox system was filed in March 2003 (PCT WO03/063697). A technology assessment of Venox has been carried out by comparing the Venox results obtained from patients undergoing cardio-thoracic surgery with the current 'gold' standard measurements taken from a heartlung bypass machine. Statistical data analysis has confirmed that there is a strong correlation between venous oxygen saturation measured by both methods. A new Venox prototype is under development with an enhanced user interface design that uses touch screen technology for fast and simple operation.
The IPPG utilises the expertise of biomedical photonics engineering, electronic systems design and multiscale physiological modelling. The research extends the PPG portfolio indicated in Table 1 by investigating the real-time imaging of blood perfusion in tissues. In vitro and in vivo measurements of blood perfusion with oxygen supply and demand characteristics over an extended region of anatomical locations will enable bioengineers and clinical scientists to investigate effectively the processes that are responsible for the transfer of oxygen from blood to tissue cells. Currently it is not possible to measure the oxygen content of veins and arteries simultaneously and independently, and thus it is not possible to measure the consumption of oxygen in a given tissue region. Key to achieving this functionality is the use of a multi-time gating approach to deliver light of different wavelengths and intensities via non-contact IPPG. The reflected light www.instmc.org.uk Themed Paper: Innovations Towards Personalised Biomedical Photonic Devices comes from different depths of tissue from which a tomograms can be computed, using similar methods to X-ray computed tomography, though using light of different wavelengths rather than ionising radiation. For success advanced VLSI-based platforms designed with novel tool flows are required. Their use results in substantially reduced software development times while being 'correct-by-construction'. The proposed step change in computational speed will be enabled by the design of a dedicated photon transport engine using a System-onChip VLSI architecture. The third component of the IPPG technology is an adaptive opto-physiological model representation of the images obtained that comprise visual physiological information at various levels of scale simultaneously. These representations yield a powerful clinical diagnostic tool based on a case-based reasoning approach. Whereas image processing and storage will be uneventful, care will also be given to beyond storage processes such as digital preservation and archiving. This IPPG system will measure and access vascular blood perfusion, and display a map of tissue oxygen consumption over an extended tissue area without the need for direct skin contact or introducing any agent into the tissue. The proposed technology is non-invasive, safe and painless.
A systems engineering methodology has been employed to describe the pre-clinical use cases. The first use case is hospitalbased, building on existing research interests in monitoring cardiac output and managing heart failure, which can rapidly become life threatening. This condition is characterised by hypermetabolism (increased oxygen consumption, increased carbon dioxide production and impaired oxygen delivery). A second use case that is closely associated with research interests of the international community is circulation assessment in patients with diabetes. This is a disease syndrome that can manifest so-called 'diabetic foot'. This condition is an example of a peripheral vascular disease that can quickly lead to ulcers and gangrene. The treatment for the latter can often lead to amputation of the lower leg. It is anticipated that early changes in the microcirculation of the foot can be picked up by the IPPG system and appropriate treatment given to prevent further morbidity. Other use cases will be explored with specific choice depending on clinical need and opportunity.
Discussion
The research strands that have come together to provide an integrated approach to IPPG have been introduced, and component technologies can be seen in Figure 1 below. It can be argued that the application of the integrated IPPG system has a data mining and knowledge discovery component via the use of the multiscale physiological model. Use cases have been indicated that demonstrate the transformation of hospital device to one that can be used in a closed or open loop control system in the home where decisions are required as to when to provide therapeutic intervention.
Real-time assessment of blood perfusion is crucial to understand the progress of disease and give an indication of the efficiency of the cardiovascular system. The IPPG system provides a real-time diagnostic capability and assessment for use in hospitals, clinical and biomedical research, and for clinical trials of novel pharmaceuticals. It also has the possibility to make an impact within healthcare community settings, for example, via use in mobile screening facilities and use for personalised healthcare in the home. The imaging technology is significantly cost effective for microcirculation assessment but, more importantly, will encourage wider and more frequent testing of blood perfusion in peripheral tissues by clinicians and the general public.
Further use cases to explore include: Cerebral blood perfusion: An opportunity to use IPPG as a means of delivering real-time assessment of cerebral blood perfusion has been presented. For this study an existing international collaboration with Shanghai Jiao Tong University in China has been exploited. In vivo and in vitro microcirculation assessment: As IPPG can assess microcirculation in localised areas of the body, it is a useful tool for oxygen consumption monitoring in patients who have serious burns.
Monitoring of hypoxia during exercise tests: Localised mapping of oxygen consumption before, during and after exercise tests give essential information for assessing ischaemic responses. IPPG can also be used to assess hypoxia induced in athletic performance testing, including effects of exposure to extreme altitudes.
With an ability to provide rapid and effective images of peripheral tissues, the methods adopted may transfer to mainstream clinical diagnostics. Such a focus can be seen as a method to reduce risk in many use cases such as 'diabetic foot' referred to earlier in the context of the diabetic patient. Thus, this innovative imaging modality has a great potential to impact on the quality of life of the general population. Should the device in production be within the planned relatively low cost range, IPPG technologies have the added potential of being able to be afforded in third world countries where diseases of peripheral vasculature are common. Contact with the WHO Eastern Mediterranean Office in Cairo, Egypt has been made to further this opportunity.
Conclusion
This paper has presented an outline summary of bioengineering work in the Systems Engineering Innovation Centre at Loughborough University over a period of time that extends back to the 1990s. As well as demonstrating the dynamics of the work with respect to the research and innovation pipeline, an indication of how the research has moved towards the opportunity for personalised healthcare is described. There are also other healthcare use cases not referred to (e.g. monitoring of sepsis in neonates) and non-healthcare applications such as in homeland security where bio-identification using non-contact reflection PPG is a possibility. These applications indicate the scope of what can be achieved by investigating the interactions of light with matter.
